216 results about "Drug vehicle" patented technology

The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.

The present invention teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent water and a liquefied hydrocarbon gas propellant; and pharmaceutical compositions thereof.

The present invention further teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent, and a liquefied hydrocarbon gas propellant; and pharmaceutical compositions thereof.

Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

Implantable drug delivery systems target delivery of small volumes of drugs to specific tissues. In some cases, a drug delivery system includes an implantable osmotic pump connected to a drug-containing housing, with that housing connected to a needle, cochlear implant or other type of component for ultimate delivery to the target tissue. In some implementations, a subcutaneous port receives a fluid from an external pump. The port is connected to a needle or other component for delivery of one or more drugs to the target tissue. Both solid and liquid drug formulations can be used. In embodiments using solid drugs, a separate drug vehicle (such as saline) can be used to dissolve a portion of the solid drug, with the drug-loaded vehicle then delivered to the target tissue.

The invention relates to the field of high-molecular porous materials and particularly relates to a preparation method of porous chitosan-based microspheres for medicine carriers, adsorption and separation, hemostasis and wound dressing. The preparation method comprises the following steps: (a) respectively preparing solidification liquid, an emsulsifying-agent solution and a diluted-acid solution of pelletizing materials and precooling the solidification solution to minus 20 DEG C; (b) dripping the chitosan diluted-acid solution into the emsulsifying-agent solution, homogenizing and stirring to form emulsion; and (c) carrying out thermally-induced phase separation on the emulsion under the temperature ranging from minus 60 DEG C to minus 10 DEG C, adding precooled solidification liquid, carrying out reverse-phase regeneration and thus obtaining the chitosan-based porous microspheres. The preparation method has the beneficial effect that the surfaces and the inner parts of the porous microspheres have porous structures with communicated heights.

A chitosen-quaternary ammonium salt nanoparticle as the carrier of protein-type medicine is prepared through dissolving chitosan-quaternary ammonium salt in distilled water, stirring while adding solution of sodium tripolyphosphate, cross-linking, centrifugal separation, and freeze drying. It has long relesing period (6 days).

The invention provides artificial tear compositions, artificial tear-gel compositions, contact lens storage compositions, contact lens treatment compositions, ophthalmological drug vehicle compositions and topical drug vehicle compositions comprising one or more nonionic surfactants with one or more non-Newtonian viscosity enhancing excipients and one or more of a polyol and or an electrolyte and methods of their use.

An anticancer high-molecular precursor medicine C-Spacer-P, where P is high- molecular pectin, C is an anticancer medicine containing amino radical or hydroxy radical, and Spacer is the spacing radical, is prepared by bonding the amino or hydroxy of an anticancer medicine with the hydroxy, carboxy, or hydroxymethyl of high- molecular pectin via spacing radical. It is an injection suitable for the solid cancer, and cancerous ascites or hydrothorax.

Vehicle and method is disclosed for treating and/or preventing skin disorders such as acne vulgaris and which exfoliates healthy skin by a topical application. The vehicle is a formulation incorporating hypohalous acid in a suitable pharmaceutical compound. The topical application comprises administering and scrubbing a therapeutically effective amount of hypohalous acid in the vehicle. The hypohalous acid may be hypochlorous acid, hypobromous acid, or hypoiodious acid. The suitable pharmaceutical vehicles include water, solutions, cleansers, lotion, cream, paper facial masks, and gels. The scrubbing action on the skin is exerted by a mechanic tool, such as hand, cloth towel, sponge, brush, and spraying device. Methods of preparing and compounding the vehicle for topical application and of its use are also set forth.

The invention relates to a monolayer graphite oxide and magnetic ferroferric oxide nano-particle composite hybrid material, and a preparation method and application thereof. The monolayer graphite oxide and magnetic ferroferric oxide nano-particle composite hybrid material is made from raw materials of monolayer graphite oxide material and a mixture of bivalent malysite and ferric malysite by a chemical deposition method. The preparation method comprises the steps as follows: the monolayer graphite oxide is dispersed in sodium hydroxide aqueous solution to obtain monolayer graphite oxide with sodium carboxylate; then ion exchange is carried out on the mixture of monolayer graphite oxide and the bivalent malysite and the ferric malysite under the protection of nitrogen; the processed mixture is deposited by sodium hydroxide solution after excessive malysite is removed to obtain a solid product; and the solid product is separated out and dried to obtain superparamagnetic monolayer graphite oxide and ferroferric oxide nano-particle composite hybrid material. The material is used for loading drug to obtain an efficient controllable targeted drug carrier with the magnetic property of pH response. The invention has wide application prospect in the aspects of multiple targeted drug delivery, and the separation, the purification, the inspection and the like of nuclear magnetic resonance contrast medium, DAN, protein, etc.

A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.

A coated medicine layer on the scaffold in arteria coronaria for preventing angiostenosis is prepared through dissolving the aliphatic polylactone and its copolymer is solvent, adding taxusol, stirring while dissolving, filtering, coating on the scaffold, evaporating the solvent, removing the solvent for 48 hr under vacuum, and disinfecting by epoxy ethane.

A stable suspension formed of a plurality of water particles each of which is encapsulated with an amorphous silica-based material, where that plurality of encapsulated water particles is dispersed in a continuous phase formed of one or more carbon-containing materials, where the stable suspension does not include added emulsifiers. A method to prepare such stable suspensions. Personal care products comprising Applicant's stable suspensions, including skin protectants, sunscreens, moisturizers, vehicles for medicaments, antiperspirants, deodorants, pressurized products such as aerosol products, vehicles for skin treatment products and vehicles for makeup, area of the eye, lip products, mascara and color cosmetic products.

The present invention discloses a coronary artery medicine coating scaffold for inhibiting endometrial hyperplasia and preventing restenosis in the scaffold. It includes dilating scaffold base body and inner coating layer coated on the dilating scaffold base body, the above-mentioned inner coating layer is formed from medicine carrier and ligustrazine, their mass ratio is 3:1-1:3, the above-mentioned inner coating layer is one of methyl acrylate, methyl methacrylate copolymer, polylactic acid, polyglycollic acid, polymonoracemic lactic acid, polylactide-diglycolide polymer, phosphorylcholine, ethyl polyurethane inorganic micropore aluminium oxide and cellulose or their composite.

The present invention relates to a quercetin solid lipid nano granule preparation and its preparation method, belonging to the field of medicine technology. Said invention uses quercetin as raw material medicine, adopts the mixture of solid lipid, emulsifier and emulsification adjuvant as medicine carrier and utilizes a certain preparation process so as to obtain the invented product. Said invention also provides the concrete steps of said preparation process.

The invention discloses a gelatin-chitosan/montmorillonite drug carried microsphere and a preparation method thereof. The drug carried microsphere is prepared by the following steps: dissolving the hydrophilic drug in the gelatin water solution, adding montmorillonite suspended water solution, carrying out intercalation reaction to obtain solution A; dissolving the chitosan in the acetic acid water solution, stirring and dissolving to obtain solution B; stirring and emulsifying liquid paraffin wax and span-80 to obtain C; adding solution B into solution A, carrying out intercalation reaction, adding C, stirring, standing, dropwise adding glutaric dialdehyde water solution, crosslinking and curing, adding isopropyl alcohol and stirring, removing supernate after standing and delaminating, vacuum filtrating to remove liquid; and washing with anhydrous ether and isopropyl alcohol in sequence, and drying to obtain the microsphere. The drug carried microsphere in the invention has good tissue compatibility, low toxicity or no toxicity, and is a drug carried material with excellent performance. The method in the invention can reduce the dosage of chemical crosslinking agent, lower the toxity of the microsphere, dramatically lower the rate of drug release, and further improve slowly controlled release ability of the drugs.

The invention discloses a preparation method of porous ferroferric oxide composite nanometre microspheres efficiently-loaded with pharmorubicin. The preparation method comprises the following steps: dissolving ferric salts in polyhydric alcohols, adding a surfactant and urea to form a mixed solution, placing the mixed solution in a reaction device and sealing, then reacting at 150-250 DEG C, after that, washing and drying the precipitate, then carrying out amination on porous Fe3O4 microspheres, adding a condensing agent and then carrying out an aminocarboxylic condensation reaction to realize the modification of sodium alginate for the Fe3O4 microspheres, finally loading pharmorubicin by taking the microspheres as carriers. The invention develops a preparation method of a magnetic-targeted medicine carrier which is simple in process, low in cost, high in loading rate, low in toxicity and good in biocompatibility, and the preparation method is of great significance on the popularization of the application of the magnetic-targeted medicine carrier in treatment on breast cancer.

The invention discloses a protein-polyphenol composite microsphere as well as a preparation method and application thereof. The preparation method comprises the following steps: mixing a protein extract aqueous solution and a polyphenol compound aqueous solution, initiating crosslinking reaction by a compound with free aldehyde, and regulating and controlling through reaction between the protein extract and the polyphenol compound to obtain the protein-polyphenol composite microsphere with wide grain diameter range distribution (10 mum to 10 nm) and regulable and controllable grain size. The protein-polyphenol composite microsphere obtained through preparation can transmit the polyphenol compound, the protein extract and the aldehyde compound which serve as the reaction raw materials, alsocan transmit a medicine interacted with the protein and the polyphenol, and can effectively enhance the antitumor effect of the medicine when serving as a tumor medicine carrier.